MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that
markets its RIO® Robotic Arm Interactive Orthopedic surgical
platform, MAKOplasty® joint specific applications and proprietary
RESTORIS® implants that together enable orthopedic surgeons to
consistently, reproducibly and precisely treat patient specific
osteoarthritic disease, today announced that Ian Dawson has been
appointed to the position of Senior Vice President of Marketing,
assuming responsibility for MAKO's commercial marketing activities,
which were formerly overseen by Ivan Delevic, who is transitioning
to the position of Senior Vice President of Corporate Development.
Mr. Dawson and Mr. Delevic will report to Maurice R. Ferré,
M.D., MAKO's President and Chief Executive Officer.
Mr. Dawson has over 25 years of experience in marketing, with
the majority of such experience in the medical device field. From
June 2008 through May 2013, Mr. Dawson served as Vice President of
North America Marketing for Smith & Nephew Advanced Wound
Management, a manufacturer and supplier of advanced wound dressings
and devices, where he was responsible for managing the entire
marketing function for North America. From May 2004 to June 2008,
Mr. Dawson held various marketing leadership positions with Zimmer,
Inc., a manufacturer and supplier of orthopedic implants and
surgical products, including Senior Director of U.S. Knee
Marketing, where he was responsible for directing all marketing
programs and activities related to Zimmer's knee products.
From July 2001 to April 2004, he served as the Vice President -
Product Group Knee, for Centerpulse Orthopedics Ltd., a
manufacturer and supplier of orthopedic implants. Mr. Dawson holds
a B.S. in Applied Biology from Chelsea College, University of
London and a Diploma in Management Studies from Exeter College of
Plymouth Polytechnic.
"Based on his impressive background and experience in
orthopedics, Ian will be a valuable addition to the MAKO team,"
said Dr. Ferré.
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its
RIO® Robotic-Arm Interactive Orthopedic system, joint specific
applications for the knee and hip, and proprietary RESTORIS®
implants for orthopedic procedures called MAKOplasty®. The RIO is a
surgeon-interactive tactile surgical platform that incorporates a
robotic arm and patient-specific visualization technology, which
enables precise, consistently reproducible bone resection for the
accurate insertion and alignment of MAKO's RESTORIS implants. The
MAKOplasty solution incorporates technologies enabled by an
intellectual property portfolio including more than 300 U.S. and
foreign, owned and licensed, patents and patent applications.
Additional information can be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing," or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability
to control or predict. Such factors, among others, may have a
material adverse effect on MAKO's business, financial condition and
results of operations and may include the potentially significant
impact of a continued economic downturn or delayed economic
recovery on the ability of MAKO's customers to secure adequate
funding, including access to credit, for the purchase of MAKO's
products or cause MAKO's customers to delay a purchasing decision,
changes in general economic conditions and credit conditions,
changes in the availability of capital and financing sources for
our company and our customers, unanticipated changes in the timing
and duration of the sales cycle for MAKO's products or the vetting
process undertaken by prospective customers, changes in competitive
conditions and prices in MAKO's markets, changes in the
relationship between supply of and demand for our products,
fluctuations in costs and availability of raw materials, finished
goods, and labor, changes in other significant operating expenses,
slowdowns, delays, or inefficiencies in MAKO's product research and
development cycles, unanticipated issues relating to intended
product launches, decreases in sales of MAKO's principal product
lines, decreases in utilization of MAKO's principal product lines
or in procedure volume or system utilizations, increases in
expenditures related to increased or changing governmental
regulation or taxation of MAKO's business, both nationally and
internationally, unanticipated issues in complying with domestic or
foreign regulatory requirements related to MAKO's current products,
including initiating and communicating product actions or product
recalls and meeting Medical Device Reporting requirements and other
required reporting to the United States Food and Drug
Administration, or securing regulatory clearance or approvals for
new products or upgrades or changes to MAKO's current products,
developments adversely affecting our actual and potential sales
activities outside the United States, increases in cost containment
efforts by group purchasing organizations, the impact of the United
States healthcare reform legislation enacted in March 2010 on
hospital spending, reimbursement, unanticipated changes in
reimbursement to our customers for our products, and the taxing of
medical device companies, any unanticipated impact arising out of
the securities class action or any other litigation, inquiry, or
investigation brought against MAKO, loss of key management and
other personnel or inability to attract such management and other
personnel, increases in costs of retaining a direct sales force and
building a distributor network, unanticipated issues related to, or
unanticipated changes in or difficulties associated with, the
recruitment of agents and distributors of our products, and
unanticipated intellectual property expenditures required to
develop, market, and defend MAKO's products or market position.
These and other risks are described in greater detail under Item
1A, "Risk Factors," in MAKO's periodic filings with the Securities
and Exchange Commission, including MAKO's annual report on Form
10-K for the year ended December 31, 2012 filed on February 28,
2013. Given these uncertainties, undue reliance should not be
placed on these forward-looking statements. MAKO does not undertake
any obligation to release any revisions to these forward-looking
statements publicly to reflect events or circumstances after the
date of this press release or to reflect the occurrence of
unanticipated events.
"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo,
whether standing alone or in connection with the words "MAKO
Surgical Corp." are trademarks of MAKO Surgical Corp.
CONTACT: Investors:
MAKO Surgical Corp.
954-628-1706
investorrelations@makosurgical.com
or
Westwicke Partners
Mark Klausner
443-213-0500
makosurgical@westwicke.com
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024